Karo Pharma Smart choices for everyday healthcare About Products Karo Everyday Investors News & Press English Financial reports Annual reports 2020, 2019, 2018, 2017, 2016, 2015, 2014, 2013 Recent reports Select year 28 October, 2021 Karo Pharma Quarterly report Q3 2021 July – September Revenues amounted to MSEK 738.5 (679.1), corresponding to an increase of +9% for the period.The organic growth1 during the third quarter was +13%. The currency impact in the quarter was 0% while the divestments generated an effect of -4%.EBIT (Operating Profit) amounted to MSEK 99.5 (43.7), corresponding to an increase of 127%.EBITDA1... 22 July, 2021 Interim report Q2 2021 April – June Revenues amounted to MSEK 747.9 (688.9), corresponding to an increase of +9% for the period. The organic growth1 during the second quarter was +8%. The currency impact in the quarter was 0% while the acquisitions of the product portfolios Pevaryl® from Johnson & Johnson and Flux®, Decubal®, Apobase®, Lactocare® from Teva generated... 21 April, 2021 Interim report Q1 2021 January – March Revenues amounted to MSEK 713.0 (793.6), corresponding to a decrease of -10% for the period. The organic growth* during the first quarter was -16%. The currency impact in the quarter was -1% while the acquisitions of the product portfolios Proct® from Leo Pharma and Pevaryl® from Johnson & Johnson generated growth of... 30 March, 2021 Karo Pharma publishes the 2020 annual report Today, on 30 March 2021, Karo Pharma is publishing its annual report for 2020 on the company’s website, www.karopharma.com. For further information, please contact: Jon Johnsson, CFO, 073-507 88 61, jon.johnsson@karopharma.com The Annual Report is published in Swedish and English. The Swedish version represents the original version and has been translated into English. This information... 18 February, 2021 Year-end report 2020 Q4, October – December Net sales amounted to MSEK 721.2 (649.3). This corresponds to an increase of 11% for the period. The organic growth* during the fourth quarter was +1%. The currency impact in the quarter was -1% while the acquisitions of the product portfolios Proct® from Leo Pharma and Pevaryl® from Johnson & Johnson... Products Financial reports Financial Press releases Contact Karo Pharma Follow us on LinkedIn Copyright© Karo Pharma AB 2021 Cookies are required for our website to function optimally and to improve the user experience. By browsing further, you accept our use of cookies.» Privacy policy Approve